Helpt u ons aan 500 donateurs?

22 november 2018: Lees ook dit artikel: 

https://kanker-actueel.nl/maretakinjecties-hoge-dosis-doen-kanker-volledig-verdwijnen-bij-vrouw-met-recidief-van-merkelcel-carcinoom-75-jaar-en-bij-vrouw-met-borstkanker-in-beide-borsten-50-jaar-zonder-andere-behandelingen-beide-vrouwen-leven-al-jaren-zonder-kanker.html

25 januari 2018: Bron: Medicine (Baltimore). 2017 Nov; 96(46): e8731: Published online 2017 Nov 17.

Jaren geleden maakte ik een reportage over de maretak in Duitsland. (of zie in gerelateerde artikelen). Hier een bijzonder ervaringsverhaal en uitstekend gedocumenteerde case studie over het effect van maretak injecties bij een kankerpatiënt.

Een nu 66 jarige vrouw die in 2012 werd gediagnosteerd met een recidief van eerder chirurgisch verwijderde melanoom maar nu in de lymfklieren uitgezaaide melanoom weigerde chemo en koos voor immuuntherapie met maretakinjecties met hoge dosis Viscum Album. En met een uitstekend resultaat want zij kwam binnen ca. 2 jaar maretakinjecties in een complete remissie en is dat nu al ruim 5 jaar. Na ca. 1,5 jaar vanaf de start van de maretakinjecties waren alle zichtbare tumoren verdwenen. Inmiddels is de vrouw nu dus al 5 jaar verder en blijkt nog steeds kankervrij. En voelt zich uitstekend.

Zie hier Petscan beeld voor en na de maretakinjecties. (tekst gaat verder onder scanbeeld.

maretak studie scanbeeld van vrouw

De vrouw had voor het melanoom bij haar werd geconstateerd dus al eerder een melanoom gehad en deze was chirurgisch verwijderd. 4 jaar later (2012) kreeg ze een recidief met uitzaaiingen in de lymfklieren. Het melanoom was BRAF negatief waardoor ze niet in aanmerking kwam voor immuuntherapie met een anti-PD medicijn. Ook had ze eerder in haar leven veel problemen met haar gezondheid gehad.  De vrouw is onderwijzeres en koos heel bewust voor de maretakinjecties en daarnaast een gezonde leefstijl en wist heel goed wat voor risico's ze nam. Maar zij deed dat bewust. 

Aanvullend gebruikte de vrouw ook voedingssupplementen, met name sodium, calcium, potassium, en magnesium, en zij gebruikte ook visoliecapsules.

Wat ik mooi vind is dat in deze case studie zij ook haar persoonlijke keuze toelicht. Ik vertaal deze maar niet want ik wil geen fouten maken in de vertaling (anders vertaalt u zelf met google translation rechtsboven dit artikel).

4. Patient's view

Following the diagnosis of the metastases, I was told at the University Hospital that it would most likely be a month before further therapy was continued. During this time, I found out about intensive Mistletoe Therapy and the hospital offering Anthroposophic Medicine. I learnt that I could have confidence in myself and that I could contribute to my own self-healing process. I realized that my own commitment to becoming healthy was needed, and learned to be grateful for everything that was healthy in me. This commitment to my own health also involved the development of an awareness of my life, including uncovering all those things which were sabotaging me from the inside. Because of this, I was able to find and take my own path in therapy—even if there were doctors who wanted to convince me not to take this path. I was able to tolerate the Mistletoe Therapy, with its high fever and side effects, as well as the sometimes painful injections, because I felt safe and confident in the treatment.

Hier uit het studierapport een grafiek over de loop van de tijd die uitstekend weergeeft hoe haar proces verliep. Zij is altijd onder controle gebleven van haar behandelend arts. 

An external file that holds a picture, illustration, etc.
Object name is medi-96-e8731-g002.jpg

Ook uit het studierapport een grafiek hoe de koorts bij haar verliep, want de hoge dosis kan dus soms hoge koorts veroorzaken:

An external file that holds a picture, illustration, etc.
Object name is medi-96-e8731-g003.jpg

Conclusie

Op basis van deze case studie en eerder gemelde individuele patiënten ervaringen lijkt een hoge dosis Viscum Album (VAE) een positief therapeutisch effect te hebben bij uitgezaaide melanomen ( MCM), vooral bij gebruik in hoge doseringen. Van ML en VT is bekend dat ze directe cytotoxische eigenschappen hebben en effect hebben op immuunwegen van het specifieke en niet-specifieke immuunsysteem en zouden op deze manier kunnen hebben bijgedragen aan de tumorcontrole in dit geval. Verder onderzoek naar de veiligheid en effectiviteit van hooggedoseerde en intraveneuze en intralesionale VAE, met name in MCM, is geboden

In het volledige studierapport: Complete remission and long-term survival of a patient with melanoma metastases treated with high-dose fever-inducing Viscum album extract wordt gedetailleerd beschreven hoe de vrouwm is behandeld en wat zij daarnaast nog meer nam aan voedingssupplementen. Hier het abstract met referentielijst.

Complete remission and long-term survival of a patient with melanoma metastases treated with high-dose fever-inducing Viscum album extract

Medicine (Baltimore). 2017 Nov; 96(46): e8731.
Published online 2017 Nov 17. doi:  10.1097/MD.0000000000008731
PMCID: PMC5704862

Complete remission and long-term survival of a patient with melanoma metastases treated with high-dose fever-inducing Viscum album extract

A case report
Monitoring Editor: Satyabrata Pany.

Abstract

Introduction:

Metastatic malignant cutaneous melanoma (MCM)—a highly immunogenic cancer—typically has a poor prognosis. Viscum album extracts (VAEs) have strong immune-stimulating, apoptogenic, and cytotoxic effects.

Case presentation:

A 66-year-old MCM patient with newly diagnosed lymph node metastases opted for sole VAE treatment. VAEs were initially applied subcutaneously, and then later in exceptionally high, fever-inducing doses, both intravenously and intralesionally. The metastases shrunk over the following months, and after 2 years, all lesions had completely remitted (regional and hilar lymph nodes). The patient has been tumor free for 3.5 years at the time of publication (and for 5 years since initiation of intensified VAE treatment). Besides fever and flu-like symptoms, no side effects occurred.

Discussion:

We presume that VAE triggered an increased release of tumor-associated antigens, enhanced immunologic recognition, and increased immune response against the tumor tissue and induced tumor remission.

7. Conclusion

On the basis of this case and earlier reported cases, VAE seems to have a positive potential in MCM, especially when used in high dosages. ML and VT are known to have direct cytotoxic properties and stimulate immune pathways of the specific and unspecific immune system and in this way might have contributed to tumor control in this case. Further research on the safety and effectiveness of high-dose and intravenous and intralesional VAE, particularly in MCM, is warranted.

Acknowledgments

We thank the research department of the Klinik Arlesheim for providing the temperature data of the patient and for practical help, Dr. Helmut Kiene for revision of the manuscript, and the “Stiftung Integrative Medizin” for financial support. This case report was prepared following the CARE Guidelines.

Footnotes

Abbreviations: AJCC = American Joint Committee on Cancer, BRAF = rapidly growing fibrosarcoma type B gene, FDG = Fludeoxyglucose (18F), MCM = malignant cutaneous melanoma, ML = mistletoe lectin, PET-CT = positron emission tomography–computed tomography, UICC = Union internationale contre le cancer, VAE = Viscum album extracts, VT = viscotoxin.

Authorship: PGW, AH, and GSK contributed to the case report design. AH was the physician in charge and provided the patient's information. PGW and AH collected and provided the data. PGW was the principle author of the paper, had full access to all data, and is the guarantor. GSK supervised the case report and publication processes.

Funding/support: This case report was prepared following the CARE Guidelines.

Informed consent was received from the patient for the publication of the report and accompanying images. The patient read the submission version of the report and confirmed its content.

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: IFAEMM has received restricted research grants, honoraria, and travel expenses from Weleda, Abnoba, and Helixor. None of them had any influence on the design, conduction, analysis, and publication of the study. AH declared no conflict of interest.

References

[1] Millet A, Martin AR, Ronco C, et al. Metastatic melanoma: insights into the evolution of the treatments and future challenges: metastatic melanoma. Med Res Rev 2017;37:98–148. [PubMed]
[2] Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 2009;19:275–82. [PubMed]
[3] Kölmel KF, Pfahlberg A, Mastrangelo G, et al. Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer. Melanoma Res 1999;9:511–9. [PubMed]
[4] Pfahlberg A, Schneider D, Uter W, et al. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J Invest Dermatol 2002;119:570–5. [PubMed]
[5] McDermott D, Lebbé C, Hodi FS, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 2014;40:1056–64. [PubMed]
[6] Kienle GS, Kiene H. Die Mistel in Der Onkologie - Fakten Und Konzeptionelle Grundlagen. Stuttgart, New York: Schattauer Verlag; 2003.
[7] Büssing A. Mistletoe: The Genus Viscum. Amsterdam: Harwood Academic; 2000.
[8] Podlech O, Harter PN, Mittelbronn M, et al. Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med 2012;2012:501796. [PMC free article] [PubMed]
[9] Elluru SR, Van Huyen J-PD, Delignat S, et al. Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. Anticancer Res 2009;29:2945–50. [PubMed]
Singh BN, Saha C, Galun D, et al. European Viscum album: a potent phytotherapeutic agent with multifarious phytochemicals, pharmacological properties and clinical evidence. RSC Adv 2016;6:23837–57.
Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 2007;12:103–19. [PubMed]
Kienle GS, Kiene H. Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 2010;9:142–57. [PubMed]
Troger W, Galun D, Reif M, et al. Viscum album [L] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer 2013;49:3788–97. [PubMed]
Kleeberg UR, Suciu S, Bröcker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. Eur J Cancer 2004;40:390–402. [PubMed]
Augustin M, Bock P, Hanisch J, et al. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC Stage II and III) with a standardized fermented European Mistletoe (Viscum album L.) extract. Arzneimittelforschung 2005;55:38–49. [PubMed]
von Laue H-B. Altmeyer P, Hoffmann K, Stücker M, editors. Mistletoe treatment for melanoma brain metastases: a single case. Skin Cancer and UV Radiation. Berlin, Heidelberg: Springer Berlin Heidelberg; 1997. 1315–22.
Kirsch A. Successful treatment of metastatic malignant melanoma with viscum album extract (Iscador® M). J Altern Complement Med 2007;13:443–6. [PubMed]
Orange M, Fonseca M, Lace A, et al. Durable tumour responses following primary high-dose induction with mistletoe extracts: two case reports. Eur J Integr Med 2010;1:227.
Orange M, Lace A, Fonseca M, et al. Durable regression of primary cutaneous B-cell lymphoma following fever-inducing mistletoe treatment: two case reports. Global Adv Health Med 2012;1:18–25. [PMC free article] [PubMed]
Werthmann PG, Strater G, Friesland H, et al. Durable response of cutaneous squamous cell carcinoma following high-dose peri-lesional injections of Viscum album extracts: a case report. Phytomedicine 2013;20:324–7. [PubMed]
Werthmann PG, Helling D, Heusser P, et al. Tumour response following high-dose intratumoural application of Viscum album on a patient with adenoid cystic carcinoma. BMJ Case Rep 2014;2014:pii: bcr2013203180. [PMC free article] [PubMed]
Orange M, Reuter U, Hobohm U. Coley's lessons remembered: augmenting mistletoe therapy. Integr Cancer Ther 2016;15:502–11. [PMC free article] [PubMed]
Mabed M, El-Helw L, Shamaa S. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer 2004;90:65–9. [PMC free article] [PubMed]
Mahfouz M, Ghaleb H, Hamza M, et al. Multicenter open labeled clinical study in advanced breast cancer patients. A preliminary report. J Egypt Nat Cancer Inst 1999;11:221–7.
Kienle GS, Grugel R, Kiene H. Safety of higher dosages of Viscum album L. in animals and humans: systematic review of immune changes and safety parameters. BMC Complement Altern Med 2011;11:72. [PMC free article] [PubMed]
Iscador AG, editor. ISCADOR in der Tumortherapie Empfehlungen für die Behandlung in Deutschland. 2nd ed. Arlesheim (CH); 2016.
Kienle GS, Mussler M, Fuchs D, et al. Intravenous mistletoe treatment in integrative cancer care: a qualitative study exploring the procedures, concepts, and observations of expert doctors. Evid Based Complement Alternat Med 2016;2016:4628287. [PMC free article] [PubMed]
Kienle GS, Mussler M, Fuchs D, et al. Individualized integrative cancer care in anthroposophic medicine: a qualitative study of the concepts and procedures of expert doctors. Integr Cancer Ther 2016;15:478–94. [PMC free article] [PubMed]
Kuby C. Mental Healing: das Geheimnis der Selbstheilung. München: Kösel; 2010.
Maletzki C, Linnebacher M, Savai R, et al. Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy. Cancer Immunol Immunother 2013;62:1283–92. [PubMed]
Cann SH, Van Netten JP, Van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 2003;79:672–80. [PMC free article] [PubMed]
Kienle GS. Fever in cancer treatment: Coley's therapy and epidemiologic observations. Global Adv Health Med 2012;1:92–100. [PMC free article] [PubMed]
Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother 2001;50:391–6. [PubMed]
Mahfouz M, Ghaleb H, Zawawy A, Scheffler A. Significant tumor reduction, improvement of pain and quality of life and normalization of sleeping patterns of cancer patients treated with a high dose of mistletoe. In: Annals of Oncology, Vol 9 Dordrecht, The Netherlands: Kluwer Academic Publishers; 1998:129–129.
Eldorry AK, Shaker MK, Barakat EM, et al. The effect of a mistletoe preparation with defined lectin content in advanced hepatocellular carcinoma cases. In: Hepatology. Vol 48 Hoboken, NJ: John Wiley and Sons; 2008: 497A–498A.
Steele ML, Axtner J, Happe A, et al. Safety of intravenous application of mistletoe (Viscum album L.) Preparations in oncology: an observational study. Evid Based Complement Alternat Med 2014;2014:236310. [PMC free article] [PubMed]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

Plaats een reactie ...

Reageer op "Immuuntherapie met maretak injecties met hoge dosis Viscum Album extract geeft volledige remissie en langjarige blijvende overleving van een patiënt met uitgezaaide melanoom."


Gerelateerde artikelen
 

Gerelateerde artikelen

Maretakinjecties hoge dosis >> Immuuntherapie met maretak >> Maretakinjecties - Viscum >> Voorlichtingsfilm over de >> Maretak injecties geven een >> Maretak injecties brengen >> Maretak - Viscum Album (bv. >> Maretak injecties - Viscum >> Maretak injecties - Viscum >> Maretak - Viscum Album L. >>